Abstract | BACKGROUND: METHOD: RESULTS: There was a decrease in common carotid IMT from 0.956 ± 0.140 to 0.900 ± 0.127 mm (-5.9%; P < 0.05) at 1 year and to 0.866 ± 0.130 mm (-9.4%; P < 0.01) at 6 years after adrenalectomy; in the spironolactone group, common carotid IMT decreased from 0.917 ± 0.151 to 0.900 ± 0.165 mm (-1.8%; NS) at 1 year and to 0.854 ± 0.176 mm (-6.8%; P < 0.01) at 6 years of treatment. The magnitude of improvement at 1 year was significantly higher (by 70%; P < 0.05) in the adrenalectomy group; however, the difference (by 27%) became nonsignificant at 6 years. Comparing the adrenalectomy and spironolactone groups, there was no significant difference in blood pressure decrease after treatment. CONCLUSION:
|
Authors | Robert Holaj, Ján Rosa, Tomáš Zelinka, Branislav Štrauch, Ondřej Petrák, Tomáš Indra, Zuzana Šomlóová, David Michalský, Květoslav Novák, Dan Wichterle, Jiří Widimský Jr |
Journal | Journal of hypertension
(J Hypertens)
Vol. 33
Issue 4
Pg. 874-82; discussion 882
(Apr 2015)
ISSN: 1473-5598 [Electronic] England |
PMID | 25490707
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Mineralocorticoid Receptor Antagonists
- Spironolactone
- Aldosterone
|
Topics |
- Adenoma
(complications, surgery)
- Adrenal Gland Neoplasms
(complications, surgery)
- Adrenalectomy
- Adult
- Aged
- Aldosterone
(blood)
- Blood Pressure
- Carotid Intima-Media Thickness
- Female
- Follow-Up Studies
- Humans
- Hyperaldosteronism
(drug therapy, etiology, surgery)
- Male
- Middle Aged
- Mineralocorticoid Receptor Antagonists
(therapeutic use)
- Prospective Studies
- Spironolactone
(therapeutic use)
|